News Releases Home Synthetic Biology The History of Synthetic Biology Living Medicines Designing Synthetic Biotic™ Medicines Pipeline + Programs For Patients Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News & Events News Releases Event Calendar Presentations & Publications Stock Information Corporate Governance Financials Investor Resources Items Per Page 102550 Year None2020201920182017201620152014 January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results November 5, 2019 Synlogic Announces Third Quarter 2019 Conference Call and Webcast September 30, 2019 Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) August 20, 2019 Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia August 8, 2019 Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 97 Email Alerts Contact IR RSS Feeds Print Page Email Page
Items Per Page 102550 Year None2020201920182017201620152014 January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results November 5, 2019 Synlogic Announces Third Quarter 2019 Conference Call and Webcast September 30, 2019 Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) August 20, 2019 Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia August 8, 2019 Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 97
January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs
December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference
November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results
September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure
September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)